IL-6 Inhibition Reduces STAT3 Activation and Enhances the Antitumor Effect of Carboplatin

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Wang, Zhi Yong ^a,b   Zhang, Jun Ai ^a,b   Wu, Xian Jin ^a,b   Liang, Yan Fang ^c   Lu, Yuan Bin ^a,b   Gao, Yu Chi ^a,b   Dai, You Chao ^a,b   Yu, Shi Yan ^a,b   Jia, Yan ^a,b   Fu, Xiao Xia ^a   Rao, Xiaoquan ^d   Xu, Jun Fa ^a,b   Zhong, Jixin ^d  

^a Key Laboratory for Medical Molecular Diagnostics of Guangdong Province   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c Department of Pathology   (China)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CASPASE 3; CYCLIN D1; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CELL DEATH; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; COLORECTAL TUMOR; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN D1; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84960969107     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/8026494     Document Type: Article

References (35)

1. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancerrelated inflammation, " Nature, vol. 454, no. 7203, pp. 436-444, 2008.
2. Q. Liao, Z. Zeng, X. Guo et al., "LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation, " Oncogene, vol. 33, no. 16, pp. 2098-2109, 2014.
3. D. T. Fisher, Q. Chen, J. J. Skitzki et al., "IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells, "The Journal of Clinical Investigation, vol. 121, no. 10, pp. 3846-3859, 2011.
4. T. Nagasaki, M. Hara, H. Nakanishi, H. Takahashi, M. Sato, and H. Takeyama, "Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction, " British Journal of Cancer, vol. 110, no. 2, pp. 469-478, 2014.
5. D. T. Fisher, M. M. Appenheimer, and S. S. Evans, "Thetwo faces of IL-6 in the tumor microenvironment, " Seminars in Immunology, vol. 26, no. 1, pp. 38-47, 2014.
6. H. Yu, H. Lee, A. Herrmann, R. Buettner, and R. Jove, "Revisiting STAT3 signalling in cancer: new and unexpected biological functions, " Nature Reviews Cancer, vol. 14, no. 11, pp. 736-746, 2014.
7. C. P. Belani, "Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma, " Seminars in Oncology, vol. 31, no. 14, pp. 25-33, 2004.
8. R. E. Bristow and D. S. Chi, "Platinum-based neoadjuvant chemotherapy and interval surgical cytoreductionfor advanced ovarian cancer: ameta-analysis, " Gynecologic Oncology, vol. 103, no. 3, pp. 1070-1076, 2006.
9. N. Borsellino, A. Belldegrun, and B. Bonavida, "Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines, " Cancer Research, vol. 55, no. 20, pp. 4633-4639, 1995.
10. Z. Duan, R. Foster, D. A. Bell et al., "Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer, " Clinical Cancer Research, vol. 12, no. 17, pp. 5055-5063, 2006.
11. J. Zhong, P. Yang, K. Muta et al., "Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice fromlethal dose of LPS-induced septic shock, " PLoS ONE, vol. 5, no. 3, Article ID e9593, 2010.
12. G.-J. Zhang and I. Adachi, "Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma, " Anticancer Research, vol. 19, no. 2, pp. 1427-1432, 1999.
13. M. Plante, S. C. Rubin, G. Y. Wong, M. G. Federici, C. L. Finstad, and G. A. Gastl, "Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer, " Cancer, vol. 73, no. 7, pp. 1882-1888, 1994.
14. M. B. Nilsson, R. R. Langley, and I. J. Fidler, "Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine, " Cancer Research, vol. 65, no. 23, pp. 10794-10800, 2005.
15. J. Kaminska, M. P. Nowacki, M. Kowalska et al., "Clinical significance of serumcytokinemeasurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I-an independent prognostic factor, " Tumor Biology, vol. 26, no. 4, pp. 186-194, 2005.
16. J. Shimazaki, Y. Goto, K. Nishida et al., "In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression, " Oncology, vol. 84, no. 6, pp. 356-361, 2013.
17. F. Esfandi, S. Mohammadzadeh Ghobadloo, and G. Basati, "Interleukin-6 level in patients with colorectal cancer, " Cancer Letters, vol. 244, no. 1, pp. 76-78, 2006.
18. S. Cohen, I. Bruchim, D. Graiver et al., "Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2, " Journal of Molecular Medicine, vol. 91, no. 3, pp. 357-368, 2013.
19. K. Leslie, C. Lang, G. Devgan et al., "Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3, " Cancer Research, vol. 66, no. 5, pp. 2544-2552, 2006.
20. A. G. Porter and R. U. Jänicke, "Emerging roles of caspase-3 in apoptosis, " Cell Death and Differentiation, vol. 6, no. 2, pp. 99-104, 1999.
21. D. T. Alexandrescu, J. P. Dutcher, and P. H. Wiernik, "Metastatic melanoma: is biochemotherapy the future?" Medical Oncology, vol. 22, no. 2, pp. 101-111, 2005.
22. M. B. Atkins, "Cytokine-based therapy and biochemotherapy for advanced melanoma, " Clinical Cancer Research, vol. 12, no. 7, pp. 2353s-2358s, 2006.
23. L. A. Emens, "Chemoimmunotherapy, " Cancer Journal, vol. 16, no. 4, pp. 295-303, 2010.
24. J. Delgado, T. Baumann, G. Ghita, and E. Montserrat, "Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy, " Current Pharmaceutical Design, vol. 18, no. 23, pp. 3356-3362, 2012.
25. C. S. Tamand M. J. Keating, "Chemoimmunotherapy of chronic lymphocytic leukemia, " Nature Reviews Clinical Oncology, vol. 7, no. 9, pp. 521-532, 2010.
26. S. Verma, T. Petrella, C. Hamm, K. Bak, and M. Charette, "Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline, " Current Oncology, vol. 15, no. 2, pp. 85-89, 2008.
27. P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Müller-Newen, and F. Schaper, "Principles of interleukin (IL)-6-type cytokine signalling and its regulation, " The Biochemical Journal, vol. 374, no. 1, pp. 1-20, 2003.
28. H. Knüpfer and R. Preiß, "Significance of interleukin-6 (IL-6) in breast cancer (review), " Breast Cancer Research and Treatment, vol. 102, no. 2, pp. 129-135, 2007.
29. S. Grivennikov, E. Karin, J. Terzic et al., "IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, " Cancer Cell, vol. 15, no. 2, pp. 103-113, 2009.
30. M. Lesina, S. M. Wörmann, P. Neuhöfer, L. Song, andH. Algül, "Interleukin-6 in inflammatory and malignant diseases of the pancreas, " Seminars in Immunology, vol. 26, no. 1, pp. 80-87, 2014.
31. F. R. Greten, L. Eckmann, T. F. Greten et al., "IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer, " Cell, vol. 118, no. 3, pp. 285-296, 2004.
32. W. E. Naugler, T. Sakurai, S. Kim et al., "Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production, " Science, vol. 317, no. 5834, pp. 121-124, 2007.
33. M. Itoh, H. Chiba, T. Noutomi, E. Takada, and J. Mizuguchi, "Cleavage of Bax- and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line, " Oral Oncology, vol. 36, no. 3, pp. 277-285, 2000.
34. A. Xiong, Z. Yang, Y. Shen, J. Zhou, andQ. Shen, "Transcription factor STAT3 as a novelmolecular target for cancer prevention, " Cancers, vol. 6, no. 2, pp. 926-957, 2014.
35. R. L. Carpenter and H.-W. Lo, "STAT3 target genes relevant to human cancers, " Cancers, vol. 6, no. 2, pp. 897-925, 2014.